Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 249165
Corporate User License Price USD 10500
Corporate User License Price INR 747495
Site License Price USD 7000
Site License Price INR 498330
Request a Quote

Report Title

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Pipeline Review, H1 2017



Executive Summary

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Pipeline Review, H1 2017

Summary

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-5-HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin (5-HT). The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal and Genetic Disorders which include indications Psychiatric Disorders, Bipolar Disorder (Manic Depression), Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Major Depressive Disorder, Anxiety Disorders, Cognitive Disorders, Fragile X Syndrome, Inflammatory Pain, Irritable Bowel Syndrome, Migraine, Neuropathic Pain, Pervasive Developmental Disorder (PDD), Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Social Anxiety Disorders (SAD) and Tourette Syndrome.

The latest report 5-Hydroxytryptamine Receptor 7-Pipeline Review, H1 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

The report reviews 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics and enlists all their major and minor projects

The report assesses 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Overview

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Companies Involved in Therapeutics Development

Adamed Sp z oo

Astellas Pharma Inc

Braeburn Pharmaceuticals Inc

H. Lundbeck A/S

Johnson & Johnson

Reviva Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Drug Profiles

ADN-1184-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADN-3662-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-9242-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DDD-028-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-18038683-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lurasidone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx-519-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Alpha 2 Adrenergic Receptor and Antagonize 5-HT7 and 5-HT5A Receptors for Psychiatric Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vortioxetine hydrobromide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Dormant Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Discontinued Products

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7)-Product Development Milestones

Featured News & Press Releases

Jun 09, 2017: Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression

May 22, 2017: Sunovion Announces Positive Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression at Annual American Psychiatric Association Meeting

May 16, 2017: Sunovion to Present Data on Latuda (lurasidone HCl) at Annual American Psychiatric Association Meeting

Mar 31, 2017: Sunovion to Present Data on LATUDA (lurasidone HCI) at the 25th European Congress of Psychiatry

Feb 27, 2017: Sunovion Announces Positive Topline Results from Study Evaluating Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression

Jan 28, 2017: Sunovion Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia

Dec 02, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 55th Annual Meeting of the American College of Neuropsychopharmacology

Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)

Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia

Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress

Aug 08, 2016: Sunovion Announces Publication of Data Evaluating Dose Escalation of Latuda (lurasidone HCl) in the Treatment of Schizophrenia

Jun 02, 2016: Trintellix (vortioxetine) Now Available in U.S. Pharmacies

May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression

May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016

May 16, 2016: Takeda and Lundbeck Present Vortioxetine Data at the American Psychiatric Association 2016 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Type,, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Adamed Sp z oo, H1 2017

Pipeline by Astellas Pharma Inc, H1 2017

Pipeline by Braeburn Pharmaceuticals Inc, H1 2017

Pipeline by H. Lundbeck A/S, H1 2017

Pipeline by Johnson & Johnson, H1 2017

Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Adamed Sp z oo

Astellas Pharma Inc

Braeburn Pharmaceuticals Inc

H. Lundbeck A/S

Johnson & Johnson

Reviva Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Therapeutic Products under Development, Key Players in 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Therapeutics, 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Pipeline Overview, 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Pipeline, 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person